Therapeutic drug monitoring‐guided definition of adherence profiles in resistant hypertension and identification of predictors of poor adherence

Arterial hypertension is an important cardiovascular risk factor. A substantial proportion of patients show resistance to antihypertensive treatment but poor adherence to medication regimens is also a significant cause of treatment failure. In this context, therapeutic drug monitoring (TDM) could be useful. The objective of this study was to assess adherence to treatment in patients with resistant hypertension by TDM and to identify parameters that predict nonadherence.

[1]  Alasdair J. G. Gray,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..

[2]  M. Burnier,et al.  Drug adherence in hypertension , 2017, Pharmacological research.

[3]  G. di Perri,et al.  UHPLC–MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples , 2017, Journal of pharmaceutical and biomedical analysis.

[4]  J. Václavík,et al.  Heart rate is a useful marker of adherence to beta-blocker treatment in hypertension , 2017, Blood pressure.

[5]  N. Samani,et al.  Risk Factors for Nonadherence to Antihypertensive Treatment , 2017, Hypertension.

[6]  S. Laurent,et al.  Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. , 2017, Journal of hypertension.

[7]  J. Schwartz,et al.  Masked tachycardia. A predictor of adverse outcome in hypertension , 2017, Journal of hypertension.

[8]  G. di Perri,et al.  UHPLC-MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. , 2016, Journal of pharmaceutical and biomedical analysis.

[9]  J. Staessen,et al.  Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension , 2016, Hypertension.

[10]  B. Davis,et al.  The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. , 2016, Hypertension.

[11]  W. White,et al.  Severe and refractory hypertension in a young woman. , 2016, Journal of the American Society of Hypertension : JASH.

[12]  F. Veglio,et al.  Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs , 2016, High Blood Pressure & Cardiovascular Prevention.

[13]  M. Uder,et al.  Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation , 2016, Journal of the American Heart Association.

[14]  M. Ruzicka,et al.  Can Drugs Work in Patients Who Do Not Take Them? The Problem of Non-adherence in Resistant Hypertension , 2015, Current Hypertension Reports.

[15]  P. Gosse,et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.

[16]  P. Muntner,et al.  Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence? , 2015, Journal of hypertension.

[17]  W. Haverkamp,et al.  Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension , 2014, Journal of hypertension.

[18]  E. Vermeire,et al.  The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review , 2014, BMC Family Practice.

[19]  Nilesh J Samani,et al.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis , 2014, Heart.

[20]  C. Ayers,et al.  Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. , 2014, Journal of the American College of Cardiology.

[21]  M. Burnier,et al.  State-of-the-art treatment of hypertension: established and new drugs. , 2014, European heart journal.

[22]  T. Zelinka,et al.  Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis , 2013, Journal of hypertension.

[23]  M. Kivimäki,et al.  Adherence to antihypertensive therapy prior to the first presentation of stroke in hypertensive adults: population-based study. , 2013, European heart journal.

[24]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.

[25]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[26]  R. Fagard.  Resistant hypertension , 2011, Heart.

[27]  K. Reynolds,et al.  Low Medication Adherence and the Incidence of Stroke Symptoms Among Individuals With Hypertension: The REGARDS Study , 2011, Journal of clinical hypertension.

[28]  H. Krum,et al.  Renal denervation and hypertension. , 2011, American journal of hypertension.

[29]  Jens Jordan,et al.  Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. , 2010, Journal of the American College of Cardiology.

[30]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.

[31]  Ross T Tsuyuki,et al.  A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.

[32]  K. Narkiewicz,et al.  Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. , 2015, Polskie Archiwum Medycyny Wewnetrznej.

[33]  D. Calhoun,et al.  Resistant hypertension: incidence, prevalence, and prognosis. , 2012, Circulation.

[34]  J. Ceral,et al.  Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy , 2011, Hypertension Research.

[35]  Daniel W. Jones,et al.  A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2008 .